AbbVie Says “V” Is For V-Shaped Recovery
Q2 Victories Include Botox Rebound, Big Skyrizi, Rinvoq Gains
Executive Summary
The firm’s major product revenues bounced back from the pandemic-troubled second quarter, with Botox recovering as predicted.
You may also be interested in...
Life After NASH For CymaBay: An Interview With CEO Sujal Shah
With up to $100m from Abingworth and a recent $75m FOPO, CymaBay has runway to await pivotal data in primary biliary cholangitis in 2023 for seladelpar, after the candidate failed in NASH. It sees a significant market opportunity in the second-line setting cornered by Intercept.
AbbVie’s Q1 Revenue Growth Outpaces Big Pharma Peers
Bouncing back from the pandemic more strongly than its peers, AbbVie sees 40% growth for Botox and Juvederm, a good launch for Ubrelvy and continued strength from its mainstays.
Keeping Track: Provention Teplizumab, AZ Anifrolumab Headline Submissions; AZ Brilinta Gains Stroke Risk Reduction Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker